The EEF2K Knockout HCT 116 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the EEF2K gene in the HCT 116 human colorectal carcinoma cell line. This product provides a stable loss-of-function model for investigating eukaryotic elongation factor 2 kinase (EEF2K) without requiring constitutive expression of targeting constructs. The polyclonal nature of the knockout pool preserves genetic heterogeneity, ensuring robust representation of various gene-disruption events across the population, and avoids the clonal selection biases inherent to monoclonal models. Researchers can thus interrogate EEF2K-mediated cellular processes within a context that more closely reflects the genetic diversity observed in tumor populations.
The host cell line, HCT 116, is a well-characterized epithelial colorectal carcinoma cell line harboring mutations in KRAS and PIK3CA, and is widely employed in cancer biology, drug screening, and signal transduction studies. Its near-diploid karyotype and strong adherent growth properties make it particularly amenable to high-throughput assays and reproducible experimental manipulations. The HCT 116 background is highly relevant for colorectal cancer research, providing a clinically meaningful platform to examine tumor-associated pathways and therapeutic vulnerabilities.
EEF2K functions as a key negative regulator of translational elongation by phosphorylating its sole substrate, elongation factor 2 (eEF2) at Thr56, thereby inhibiting ribosomal translocation. The kinase is activated by calcium/calmodulin signaling and by AMPK under energy stress, while it is inactivated through phosphorylation by mTORC1/p70S6K and PKA, linking nutrient and growth factor status to protein synthesis. EEF2K also interacts with 14-3-3 proteins, which modulate its activity and subcellular localization. Downstream consequences of EEF2K activity include suppression of global translation, induction of autophagy, modulation of apoptosis, and regulation of cell proliferation. These pathways position EEF2K at a critical nexus integrating stress signals with anabolic and catabolic cellular programs.
In the HCT 116 colorectal cancer context, disruption of EEF2K offers a powerful system to dissect the kinase??s role in cancer cell adaptation to metabolic stress, therapeutic resistance, and malignant progression. Because HCT 116 cells rely on robust protein synthesis and stress response pathways for survival and proliferation, elimination of EEF2K can reveal dependencies on translational control mechanisms. This model is thus particularly suited for interrogating how EEF2K influences autophagy, apoptosis, and cell migration under conditions such as nutrient deprivation or chemotherapeutic challenge, and for evaluating the therapeutic potential of targeting EEF2K in colorectal cancer.
These polyclonal knockout cells are applicable to a wide array of experimental approaches, including Western blotting to confirm loss of EEF2K and changes in phospho-eEF2 levels, RT-qPCR for transcriptional analyses, colony formation and migration assays for functional phenotypic screening, and phospho-specific flow cytometry to assess signaling dynamics. Translational output can be directly measured by puromycin incorporation assays or polysome profiling, while transcriptome-wide effects may be explored via RNA-seq. The cells also support drug sensitivity and metabolic studies, enabling the systematic investigation of EEF2K??s contribution to stress adaptation and therapeutic response. For further information, please contact Ascent Research.
